Inotuzumab ozogamicin consists of a humanized monoclonal antibody against CD22 (inotuzumab), linked to a cytotoxic agent from the class of calicheamicins called ozogamicin.

Liek obsahuje liečivo inotuzumab ozogamicín, ktoré patrí medzi protinádorové lieky nazývané antineoplastiká. Viaže sa na nádorové bunky s bielkovinou nazývanou CD22. Po naviazaní sa dostane do bunky, kde sa uvoľní časť liečiva, ktorá poškodí DNA a spôsobí smrť nádorovej bunky.

Zoznam liekov s účinnou látkou inotuzumab ozogamicín. Informácie o výdaji, doplatkoch, spôsobe užívania. Rozsiahle možnosti vyhľadávania. Denne aktualizované.

Inotuzumab ozogamicin sa používa predovšetkým pri liečbe B-bunkovej akútnej lymfoblastickej leukémie (ALL), ktorá sa vrátila po predchádzajúcej liečbe alebo na ňu nereaguje.

Inotuzumab Ozogamicin (IO) is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL).

This page contains brief information about inotuzumab ozogamicin and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

BESPONSA® (inotuzumab ozogamicin) is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year of age and older.

We sought to determine whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, results in better outcomes in patients with relapsed or refractory acute lymphoblastic...

The efficacy of inotuzumab ozogamicin (InO) in the relapsed/refractory setting for pediatric and adult populations has led to incorporation of this targeted therapy into frontline regimens.

What is inotuzumab ozogamicin? Inotuzumab ozogamicin is a monoclonal antibody linked to a chemotherapy drug. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage.